ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Astellas To Shut Down Three R&D Sites

by Lisa M. Jarvis
May 20, 2013 | APPEARED IN VOLUME 91, ISSUE 20

Japanese pharmaceutical firm Astellas is shuttering three R&D sites in the U.S. and Japan as part of a broad overhaul of its research network. Two of the sites will be closed this year. Both came into its fold through acquisitions: the Farmingdale, N.Y., research facility of Astellas subsidiary OSI Pharmaceuticals, bought in 2010, and the Redwood City, Calif., labs of Perseid Therapeutics, purchased in 2011. In 2015, the doors will close on Astellas’ Kashima research facility in Osaka, and in-house fermentation research will end. Astellas says some functions from the three shuttered sites will be transferred to its R&D facility in Tsukuba.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment